All In Biotech

Drug Trial Radar · NCT07128550

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Dec 2026

Study completion Jul 2031

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Conditions

  • Viral Hepatitis

Interventions

  • TobevibartDrug

    Tobevibart administered by subcutaneous injection

  • ElebsiranDrug

    Elebsiran administered by subcutaneous injection

  • BulevirtideDrug

    Bulevirtide administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24Time frame: Week 24
  2. HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.Time frame: 24 Weeks after End of Treatment

Locations

38 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Innsbruck, Austria

  • Investigative Site

    Vienna, Austria

  • Investigative Site

    Bobigny, France

  • Investigative Site

    Clichy, France

  • Investigative Site

    Créteil, France

  • Investigative Site

    Le Chesnay, France

  • Investigative Site

    Limoges, France

  • Investigative Site

    Lyon, France

  • Investigative Site

    Montpellier, France

  • Investigative Site

    Pessac, France

  • Investigative Site

    Rennes, France

  • Investigative Site

    Toulouse, France

  • Investigative Site

    Villejuif, France

  • Investigative Site

    Berlin, Germany

  • Investigative Site

    Essen, Germany

  • Investigative Site

    Frankfurt am Main, Germany

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Bergamo, Italy

  • Investigative Site

    Foggia, Italy

  • Investigative Site

    Milan, Italy

  • Investigative Site

    Milan, Italy

  • Investigative Site

    Pisa, Italy

  • Investigative Site

    Torino, Italy

  • Investigative Site

    Torino, Italy

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Craiova, Romania

  • Investigative Site

    Barcelona, Spain

  • Investigative Site

    Barcelona, Spain

  • Investigative Site

    Madrid, Spain

  • Investigative Site

    Madrid, Spain

  • Investigative Site

    Santander, Spain

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

  • Investigative Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.